Application note: Rapid Analysis of Genotoxic Nitrosamines by HPLC-MS/MS
Genotoxic impurities (GTI’s) are intermediate, reactive products or degradants formed during drug synthesis, formulation or storage.
These impurities can damage human genetic material at very low levels, leading to DNA mutations which can contribute to tumorigenesis and carcinogenicity. Because of these compounds’ potencies, they pose a threat to the safety of medication. To prevent large-scale recall incidents, such as those involving nelfinavir mesylate (Viracept) in 2007, or valsartan (Diovan) in 2018, regulatory agencies including the US FDA and the European Medicines Agency (EMA), have issued guidelines on the allowable limits of genotoxic impurities in pharmaceutical products to ensure their safety. These guidelines state exposure to GTI’s must be below the threshold of toxicological concern (TTC) of 1.5 µg per day.
Related content from this organisation
- Project worth £3.1mn to develop advanced controls for biopharma manufacturing
- Global mass spectrometry market to value $7.3 billion by 2028
- Expert view: The future of biologics quality – multiple attribute methodology
- Application note: New Peak Detection Using the SCIEX OS Software 1.5 MAM Workflow
- Application note: Rapid Analysis of Genotoxic Nitrosamines by HPLC-MS/MS